

Development and evaluation of a real-time polymerase chain reaction assay for the rapid detection of *Talaromyces marneffe* MP1 gene in human plasma

Ha Thuc Ai Hien,¹ Tran Tan Thanh,¹ Nguyen Thi Mai Thu,¹ Ashley Nguyen,¹ Nguyen Tat Thanh,¹ Nguyen Phu Huong Lan,² Cameron Simmons,^{1,3} Cecilia Shikuma,⁴ Nguyen Van Vinh Chau,² Guy Thwaites^{1,5} and Thuy Le^{1,4,5}

¹Wellcome Trust Major Overseas Program, Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam, ²Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam, ³Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia, ⁴Hawaii Center for AIDS, University of Hawaii at Manoa, Honolulu, HI, USA and ⁵Centre for Tropical Medicine, Nuffield Department of Clinical Medicine, Oxford University, Oxford, UK

Summary

Penicilliosis caused by *Talaromyces marneffe* is a common AIDS-defining illness in South and Southeast Asia. Diagnosis is based on culture which can take up to 14 days for identification, leading to treatment delay and increased mortality. We developed a TaqMan real-time PCR assay targeting the MP1 gene encoding an abundant cell wall protein specific to *T. marneffe*. The assay's performance was evaluated in MP1-containing plasmids, clinical isolates, and plasma from HIV-infected patients with and without penicilliosis. The assay consistently detected 10 copies of MP1-containing plasmids per reaction and 100 *T. marneffe* yeast cells per millilitre plasma. There were no amplification with seven other *Penicillium* species and six other HIV-associated fungal pathogens tested. The assay was evaluated in 70 patients with AIDS: 50 patients with culture-confirmed penicilliosis and 20 patients with opportunistic infections other than penicilliosis. The diagnostic sensitivity was 70.4% (19/27, 95% CI: 51.5–84.1%) and 52.2% (12/23, 95% CI: 33.0–70.8%) in plasma samples collected prior to and within 48 h of antifungal therapy respectively. The diagnostic specificity was 100% (20/20, 95% CI: 83.9–100%). This assay provides a useful tool for the rapid diagnosis of *T. marneffe* infection and has the potential to improve the management of patients with penicilliosis.

Key words: TaqMan real-time polymerase chain reaction, *Talaromyces marneffe*, *Penicillium marneffe*, HIV.

Correspondence: Thuy Le, MD, DPhil, Wellcome Trust Major Overseas Program, Oxford University Clinical Research Unit, 764 Vo Van Kiet, Ward 1, District 5, Ho Chi Minh City, Vietnam.

Tel.: +84 838 384 012. Fax: +84 839 238 904.

E-mail: thuy@oucru.org, lethuy@hawaii.edu

Meeting

Data were partially presented at the 19th Conference of Retroviruses and Opportunistic Infections, Atlanta, GA, USA, 3–6 March, 2013. Poster #875.

Submitted for publication 23 March 2016

Revised 7 June 2016

Accepted for publication 8 June 2016

Introduction

Talaromyces marneffe (previously named *Penicillium marneffe*) is an emerging fungal pathogen that causes a systemic mycosis in immunocompromised and, less commonly, immunocompetent residents and travellers to Southeast Asia, India and China.^{1–3} The HIV epidemic has transformed *T. marneffe* from a rare infection to a leading AIDS-defining diagnosis in this region,^{1,4–8} trailing only tuberculosis, cryptococcosis or *Pneumocystis jiroveci* pneumonia (PJP) in incidence.^{1,7} Mortality is up to 20% despite antifungal therapy.^{5,8} The diagnosis is often delayed as it can

take up to 14 days to isolate and identify the pathogen from clinical specimens. Typical skin lesions develop in 50% to 70% of patients^{1,5} which enable a presumptive diagnosis to be made based on Gram's or Giemsa staining of skin smear. Patients without skin lesions experience a significant delay in antifungal therapy initiation.⁵ These patients have significantly higher mortality and frequently die before the diagnosis is made.^{1,5} Development of non-culture-based assays for rapid detection of *T. marneffeii* infection has the potential to improve treatment outcomes.

Several serological assays detecting antigen and antibody to *T. marneffeii* have been developed^{9–11}; however, none has been evaluated in prospective clinical studies to diagnose active infections. Polymerase chain reaction (PCR) technique offers a sensitive and specific tool to detect several invasive fungal pathogens.^{12,13} PCR-based assays have been developed to detect *T. marneffeii* in clinical isolates^{14,15} and in a small number of clinical specimens.^{16,17} TaqMan and SYBR Green real-time PCR assays evaluated in 20 and 23 patients with penicilliosis reported diagnostic sensitivities of 60% and 77% respectively; however, diagnostic specificity was not assessed.^{17,18} To date, the molecular targets of these PCR assays are based on the fungal ribosomal DNA, a highly conserved region shared by many groups of fungi, potentially compromising specificity. Here, we report the development and assessment of a TaqMan real-time PCR assay to detect *T. marneffeii* *MP1*, a novel gene encoding *T. marneffeii* cell wall manoprotein.¹⁹ *MP1* is a unique gene without homologues in sequence databases, thus cross-reaction to related fungal pathogens is minimised.

Methods

Statement of ethics

The study was approved by the Scientific and Ethical committee of the HTD. All patients gave informed consent for blood drawn for this diagnostic study.

Development of the real-time PCR assay

Oligonucleotide primers and hybridisation probe

All 23 nucleotide sequences of *T. marneffeii* *MP1* (accession number DQ08822 to DQ08845) were retrieved from GenBank and were aligned using BIOEDIT software (v7.0.1, Ibis Biosciences, Carlsbad, CA, USA). The primers and TaqMan probes were designed to be highly specific to a conserved region of *MP1* using PRIMER EXPRESS software (v2.0, Applied Biosystem, Foster City, CA, USA) (Table 1). The specificity of the primers and probe was confirmed by performing BLAST searches on GenBank showing no cross-reacting sequences with other fungi.

Template DNA preparation

Talaromyces marneffeii yeast cells were sub-cultured on Sabouraud Dextrose Agar (SDA) at 37 °C for 5–7 days until single cells were created. The cells were homogenised in 5 ml PBS (pH 7.2) containing Tween 20 (5%) (Sigma, Singapore). Cell pellets were collected by centrifugation at 8000 *g* for 5 min, and after thoroughly washed two times with PBS, cell pellets were resuspended in 5 ml PBS. Fungal DNA extraction was performed as described previously with minor modifications.¹⁸ Briefly, fungal cell wall was removed to form spheroplasts by treating 200 µl of resuspended cultured fungal isolates or plasma specimens with 600 µl sorbitol buffer (1 mol l⁻¹ sorbitol, 100 mmol l⁻¹ EDTA and 14 mmol l⁻¹ β mercaptoethanol) supplemented with 200 U lyticase enzyme (Sigma). The mixture was incubated at 30 °C for 30 min. Spheroplast DNA was extracted using QIAamp DNA blood mini kit (QIAGEN, Hilden, Germany) and was eluted in 30 µl of elution buffer.

TaqMan real-time PCR assay

Real-time PCR was performed using the Light-Cycler[®]480 (Roche Applied Science, Penzberg, Germany). The reaction was conducted in 25 µl volume containing 2.5 µl buffer 2.5× (QIAGEN), 500 nM MgCl₂ (QIAGEN), 400 nM dNTP (Invitrogen), 400 nM each primer, 200 nM TaqMan probe, one unit Hotstart

Table 1 Primers and probe for the real-time PCR assay.

Primers and probe	Nucleotide sequences ¹	Position of DQ08822	T _m (°C)
Forward primer	5'-TCTGGACGGYGTTCAGTC-3'	222–239	57
Reverse primer	3'-TGATTGCTTAAATCCTGAACA-5'	294–314	52
Probe	5'-FAM-AAAATGAGCCTCCGCTTA GCTCCATGG-BHQ1-3'	249–271	52

¹Y = T or C; 5'-FAM = 5' 6-carboxyfluorescein; BHQ, black hole quencher.

Taq polymerase (QIAGEN), and 5 µl template DNA. The real-time PCR conditions were: one cycle 95 °C 15 min, 45 cycles 95 °C 15 s, 56 °C 30 s and 72 °C 15 s. The fluorescent signal of 6-carboxyfluorescein (FAM) was detected at 72 °C in every reaction cycle. All reactions were performed in triplicate.

Assessment of sensitivity using *T. marneffeii* MP1-containing plasmids

The real-time PCR products were purified using the QIAquick[®] PCR purification kit (QIAGEN, Hidden, Germany), were cloned into pCR2.1-TOPO plasmid and electro-transformed into *E. coli* DH5αTM-T1^R (TOPO TA cloning kit, Invitrogen, Carlsbad, CA, USA). The presence of MP1 gene was confirmed by sequencing using ABI BigDye Terminate v3.1 Cycle Sequencing kit (Applied Biosystem). Successful transformants were selected by culturing *E. coli* clones overnight in liquid Luria-Bertani medium supplemented with ampicillin 100 mg ml⁻¹. Plasmids were purified using QIAprep[®] Miniprep Kit (QIAGEN), and plasmid quantity was determined using UV-spectrophotometer. To assess the analytical sensitivity of the TaqMan-PCR assay, 10-fold serial dilutions of purified plasmid DNA (10⁶ to 1 copies µl⁻¹) in sterile distilled water were tested in triplicate.

Assessment of sensitivity using *T. marneffeii* yeast cells

The sub-cultured *T. marneffeii* yeast cells prepared as above were counted on a cell counting chamber under a light microscope. Ten-fold serial dilutions of *T. marneffeii* yeast cells (10⁶–10¹ cells ml⁻¹) spiked into human plasma collected from healthy volunteers were tested in the PCR assay. A quantity of 200 µl of plasma of each dilution was used for DNA extraction.

Assessment of sensitivity and specificity using fungal isolates

Assessment of sensitivity and specificity was performed using seven clinical *T. marneffeii* isolates and six clinically related other fungal isolates, including *Candida albicans*, *Candida tropicalis*, *Cryptococcus neoformans*, *Aspergillus fumigatus*, *Aspergillus terreus* and *Aspergillus flavus*. These clinical isolates were obtained from HIV-infected patients at the Hospital for Tropical Disease (HTD) in Ho Chi Minh City. In addition, seven American Type Culture Collection (ATCC) laboratory *Penicillium* strains, including *P. chrysogenum* (ATCC 10106),

P. variabile (ATCC 32333), *P. aurantiogriseum* (ATCC 16025), *P. citrinium* (ATCC 10499), *P. crustosum* (ATCC 10122), *P. expansum* (ATCC 1117) and *P. glabrum* (ATCC 10444) were used. The fungal isolates were sub-cultured using SDA for 3–7 days at 37 °C for the yeast isolates (*T. marneffeii*, *Candida* spp., and *Cryptococcus neoformans*) and at 25 °C for the mould isolates (*Aspergillus* spp. and *Penicillium* spp.).

Assessment of the Taqman assay in plasma samples

The diagnostic performance of the assay was assessed using plasma samples of HIV-infected patients, 50 with culture-confirmed penicilliosis and 20 with other opportunistic infections (Fig. 1). The samples came from patients who participated in a case-control study to investigate the risk factors of AIDS-associated penicilliosis between January 2011 and July 2012 at the HTD. Blood culture was performed in all patients using the automated BactecTM 9240 culture system (Becton Dickinson, Sparks, MD, USA). Penicilliosis case patients were those with an illness in which *T. marneffeii* was isolated from a clinical specimen, including blood, skin scrapings, bone marrow, lymph node and/or other body fluids. Control patients were diagnosed with AIDS-associated opportunistic infections other than penicilliosis. Plasma samples for PCR testing were collected at enrolment either prior to or within the first 48 h of antifungal therapy.

Statement of safety

Clinical materials presumed to be infected with *T. marneffeii* are handled and processed according to Biosafety Level 2 (BSL-2) practices. All culture materials, whether in the yeast or the mould form, are handled in a Class II biosafety cabinet. All culture containment materials are covered with paraffin paper when transferred outside of the safety cabinet.

Results

Sensitivity for detecting MP1 gene copy number

The TaqMan-PCR assay was able to detect MP1-containing plasmids at one copy per reaction (or 30 copies ml⁻¹), but detection was consistent at 10 copies per reaction (or 300 copies ml⁻¹). Figure 2 shows the quantification of MP1-containing plasmids that were serially diluted to concentrations from 10⁶ to 10¹ and the linear regression of the Cp values vs. the log₁₀




Figure 1 Study population used to assess the real-time PCR diagnostic performance.

concentrations of *MP1* plasmids. Linearity was achieved within a range plasmid DNA from 10^6 to 10^1 copies per reaction, and the correlation coefficient $R^2 = 0.996$.

Sensitivity for detecting *T. marneffeii* yeast spiked into human plasma

The TaqMan-PCR assay was able to detect *T. marneffeii* yeast cells at a concentration of 100 cells ml^{-1} . Linearity was achieved within a range of yeast concentrations from 10^6 to 10^2 cells ml^{-1} , $R^2 = 0.997$. The calculated number of plasmids at the limit of detection of 100 cells ml^{-1} is 30 copies ml^{-1} , indicating significant DNA loss during extraction.

Specificity for detection of *T. marneffeii* among fungal isolates

The primers and probe successfully detected all seven *T. marneffeii* clinical isolates. No significant elevated signal was detected in the 13 non-*T. marneffeii* isolates. The absence of DNA was confirmed by agarose gel electrophoresis of TaqMan-PCR products derived from these non-*T. marneffeii* isolates, indicating that the assay is highly specific.

Diagnostic performance in patient plasma

The assay was evaluated in plasma samples from 50 HIV-infected patients with culture-confirmed penicilliosis and from 20 patients with other HIV-associated opportunistic infections. The assay was able to detect *T. marneffeii* *MP1* gene in 19 of 27 (70.4%, 95% CI: 51.5–84.1%) patients in whom samples were collected prior to antifungal therapy and in 12 of 23 (52.2%, 95% CI: 33.0–70.8%) patients in whom samples were collected within 48 h of antifungal therapy. Although sensitivity is lower compared to the Bactec system (44/50 patients, 88.0%, 95% CI: 76.2–94.3%), a statistical comparison between the sensitivity of the new TaqMan PCR assay and the Bactec system in the patients where both samples were collected prior to antifungal therapy did not reach significance, 19/27 (70.4%) vs. 24/27 (88.9%), P value (McNemar test) = 0.29. No visible signal was detected in all 20 plasma specimens of patients infected with other opportunistic infections, giving a clinical specificity of 100%.

Table 2 shows the C_p values in the 50 plasma samples of the patients with culture-confirmed penicilliosis, timing of blood collection with respect to antifungal therapy, and the duration of the Bactec culture system to detect fungal growth from the hospital microbiology




Figure 2 (a) Amplification plots of Mp1 plasmids with dilution concentrations from 10^6 to 10^1 copies per reaction, showing increase in the fluorescence emission of the reporter dye relative to the reference dye. (b) Linear regression of the crossing point values vs. \log_{10} concentration of Mp1 plasmids. All the samples were performed in triplicate.

laboratory. The median time to detect a growth signal in blood culture bottles using the Bactec system was 5 days (inter quartile range: 5–7). Among the 16 patients who did not have skin lesions, the PCR assay was positive in only seven (43.8%); however, sensitivity was higher, 66.7%, when blood samples were collected prior to antifungal therapy (Table 2).

Discussion

We developed a highly specific PCR assay for *T. marneffeii* detection with no amplification detected from the 13 different fungal isolates in the *Cryptococcal*, *Aspergillus*, *Candida* and *Penicillium* genera, and no

amplification was observed in plasma specimens of 20 AIDS patients infected with other HIV-associated fungal and opportunistic pathogens. The diagnostic sensitivity was 70.4% in samples collected prior to antifungal therapy, which decreased to 52.2% in samples collected within 48 h after antifungal drugs had been started, suggesting that the assay can be useful to monitor fungal clearance on therapy. With respect to the analytical sensitivity, the assay had a limit of detection of one copy of *MP1* per reaction, but it consistently detected 10 copies per reaction (or 300 copies per millilitre). In *T. marneffeii* spiked human plasma, the assay consistently detected 100 cells ml^{-1} . The analytical sensitivity of our PCR assay appears to be

Table 2 TaqMan real-time PCR detection of *T. marneffei* MP1 gene in 50 plasma samples of patients with microbiological-confirmed penicilliosis.

Patients	Time on antifungal therapy (h) ¹	Mean Cp values (standard deviation)	Specimens positive with <i>T. marneffei</i>	Time to Bactec blood culture identification (days) ²
1	0	39.5 (±0.95)	Blood and skin	9
2	0	40.0 (±0.00)	Skin	Data not available
3	0	34.4 (±0.05)	Blood and skin	Data not available
4	0	40.0 (±0.00)	Skin	Data not available
5	0	35.7 (±0.97)	Blood	3
6	0	Not detected	Skin	Data not available
7	0	40.0 (±0.00)	Blood and skin	4
8	0	Not detected	Blood	6
9	0	Not detected	Blood and skin	7
10	0	39.0 (±1.74)	Blood and skin	6
11	0	38.6 (±0.67)	Blood and skin	3
12	0	35.0 (±0.24)	Blood and skin	4
13	0	38.1 (±1.25)	Blood and skin	5
14	0	Not detected	Blood	Data not available
15	0	39.3 (±0.63)	Blood and skin	4
16	0	34.0 (±0.34)	Blood	Data not available
17	0	Not detected	Blood and skin	5
18	0	39.6 (±0.62)	Blood	6
19	0	35.2 (±0.11)	Blood and skin	5
20	0	Not detected	Blood and skin	Data not available
21	0	40.0 (±0.00)	Blood and skin	7
22	0	Not detected	Blood and skin	3
23	0	Not detected	Blood and skin	7
24	0	40.0 (±0.00)	Blood and skin	5
25	0	40.0 (±0.00)	Blood and skin	7
26	0	40.0 (±0.00)	Blood and skin	5
27	0	33.0 (±1.25)	Blood	6
28	24	Not detected	Skin	Data not available
29	24	Not detected	Blood and skin	7
30	24	38.2 (±0.23)	Blood and skin	5
31	24	37.2 (±0.10)	Blood and skin	3
32	24	Not detected	Skin	Contaminate (<i>Burkholderia cepacia</i>)
33	24	Not detected	Blood	6
34	24	40.0 (±0.00)	Blood and skin	4
35	24	40.0 (±0.00)	Blood and skin	6
36	24	Not detected	Blood	5
37	24	40.0 (±0.00)	Blood and skin	9
38	24	40.0 (±0.00)	Blood	5
39	24	Not detected	Blood	7
40	24	Not detected	Blood	5
41	24	31.0 (±1.20)	Blood and skin	3
42	24	33.0 (±0.47)	Blood and skin	5
43	24	Not detected	Blood and skin	7
44	48	37.8 (±0.33)	Skin	Data not available
45	48	Not detected	Blood	Data not available
46	48	36.9 (±0.29)	Blood	7
47	48	Not detected	Blood	6
48	48	Not detected	Blood	7
49	48	39.9 (±0.24)	Blood	5
50	48	39.3 (±0.63)	Blood and skin	7

¹Time on antifungal therapy prior to blood collection for real-time PCR assay, time 0 = prior to antifungal therapy.

²Time to detect a growth signal in blood culture bottles using the automated Bactec culture system; median: 5 days (interquartile range: 5–7). All reactions were performed in triplicate.

10-fold lower compared to the TaqMan real-time PCR assay by Pornprasert *et al.* [18] which targets the 5.8S ribosomal DNA. This may mean that there are significantly more copy numbers of the ribosomal DNA relative to the *Mp1* per *T. marneffei* yeast cell. However, the diagnostic sensitivities of the two assays (in samples collected before and after antifungal therapy) are similar, 31/50 (62.0%) vs. 12/20 (60.0%), *P* value (Fisher's Exact Test) = 1.00. The diagnostic sensitivity of our assay is lower than the recently developed SYBR Green real-time PCR assay by Sha Lu *et al.*; however, the difference in sensitivities is not statistically significant, 31/50 (62.0%) vs. 23/30 (76.7%), *P* value (Fisher's Exact Test) = 0.22. In none of these previous real-time PCR assays was clinical specificity assessed. Direct comparison of the diagnostic performance of these real-time PCR assays on the same clinical samples will be informative. Our assay is not more sensitive than the nested PCR assay developed by Pongpom *et al.* [16] which detected *T. marneffei* in 24/35 patients (68.6%); however, conventional PCR methods are slower, more labour-intensive, and is prone to post-PCR contamination comparing to real-time PCR.

Compared to the Bactec culturing method, our assay was less sensitive (70% vs. 88%), although the difference did not reach statistical significance. A major advantage of culturing is the larger volume of sample being used (approximately 5 ml of blood compared to 200 µl used in this assay). Using larger DNA extraction volume and further concentrating the DNA used in PCR reaction might increase the sensitivity of this assay.

Recently, a monoclonal-based immunoassay has been developed that detected *T. marneffei* Mp1p antigen in patient plasma with a sensitivity of 75% (15/20) and specificity of 99.4% (537/540).¹⁰ The assay has been shown to detect Mp1p antigenemia in 9.4% of more than 8000 HIV-infected patients in outpatient clinics from Guangzhou, China,²⁰ offering another tool for rapid diagnosis of *T. marneffei* infection.

A limitation of our study is that we only tested the assay on patient plasma samples. Whole blood or white blood cell buffy coat may be better diagnostic specimens as *T. marneffei* primarily replicates inside macrophages, which can be lost during plasma sample processing. Another limitation is that the *C_p* values of the PCR-positive specimens in our study are high, suggesting that the amount of pathogen DNA obtained for PCR is not high enough. Research for better ways to break down the fungal cell wall using both mechanical and chemical means during DNA

extraction and for ways to increase the amount of input DNA used in PCR assays may advance the molecular diagnostics of fungal diseases.

Despite the limitations and the need for further research to improve the sensitivity, the clear advantages of this real-time PCR assay are its speed and high specificity. It takes 5–6 h to perform, which would probably result in a next-day diagnosis in most routine laboratories. This compares to an average of 5 days to detect a growth signal in the blood culture of patients using the highly efficient Bactec system (Table 2). Additionally, identification of *T. marneffei* requires a demonstration of temperature-dependent dimorphic growth, and subculture at 25 °C generally takes another 2–3 days. This real-time PCR assay should not replace the need for conventional microbiology methods in diagnosing penicilliosis. However, in conjunction with culturing, it can be used as a rapid rule-in test that can make a significant difference in patient management by allowing antifungal therapy to begin sooner, particularly in patients without skin lesions, and has the potential to improve the outcomes of *T. marneffei*-infected patients.

Acknowledgments

We thank the patients who participated in this study. We thank Drs. Ngo Thi Kim Cuc, Nguyen Huu Chi, Vo Minh Quang, Nguyen Le Nhu Tung, Nguyen Thanh Liem, Le Duc Vinh, Ly Quoc Cong, Pham Si Lam, and nurse Phan Thi Hong Dao from the Hospital for Tropical Diseases for their support of the study and assistance with patient recruitment. We thank Drs. Dinh Nguyen Huy Man and Nguyen Thi Quynh Nga from the microbiology department of the Hospital for Tropical Diseases for providing the clinical fungal isolates for this study. We thank Dr. Chu Nguyen Thanh from the Quality Assurance and Testing Center for Microbiology in Dong Nai, Vietnam for providing the ATCC *Penicillium* strains. Lastly, we thank Drs. Marcel Wolbers and Max Caws for their critical readings and editing of the manuscript.

Conflicts of interest

We declare that we have no conflicts of interest.

Funding

The study was funded by the University of Washington Centre for AIDS Research (NIH grant P30 AI027757) and the Hawaii Centre for AIDS as an International

Junior Faculty Award (Le) and the Wellcome Trust (Hien, Thanh, Thu, Lan, Thwaites, and Le).

Author contributions

Study concept and design: Hien, Thanh TT, Simmons, Le. Obtaining funding: Le, Shikuma. Clinical and microbiology data acquisition: Le, Thanh NT, Lan, Vinh Chau. Laboratory work: Hien, Thanh, Thu, Ashley. Analysis and interpretation of data: Hien, Thanh, Le. Drafting the manuscript: Hien, Thanh TT, Le. Critical revision of the paper for intellectual contents: Thu, Ashley, Thanh NT, Shikuma, Lan, Vinh Chau, Simmons, and Thwaites. All authors contributed to and approved the final manuscript.

References

- 1 Supparatpinyo K, Khamwan C, Baosoung V, Nelson KE, Sirisanthana T. Disseminated *Penicillium marneffei* infection in Southeast Asia. *Lancet* 1994; **344**: 110–3.
- 2 Vanittanakom N, Cooper CR, Fisher MC, Sirisanthana T. *Penicillium marneffei* infection and recent advances in the molecular biology aspect. *Clin Microbiol Rev* 2006; **19**: 95–110.
- 3 Antinori S, Gianelli E, Bonaccorso C, *et al.* Disseminated *Penicillium marneffei* infection in an HIV-positive Italian patient and a review of cases reported outside endemic regions. *J Travel Med* 2006; **13**: 181–8.
- 4 Larsson M, Nguyen LHT, Wertheim HF, *et al.* Clinical characteristics and outcome of *Penicillium marneffei* infection among HIV-infected patients in northern Vietnam. *AIDS Res Ther* 2012; **9**: 24.
- 5 Le T, Wolbers M, Chi NH, *et al.* Epidemiology, seasonality, and predictors of outcome of aids-associated *Penicillium marneffei* infection in Ho Chi Minh City, Viet Nam. *Clin Infect Dis* 2011; **52**: 945–52.
- 6 Lee N. Penicilliosis: an AIDS-defining disease in Asia. *Hong Kong Med J* 2008; **14**: 88–9.
- 7 Wu TC, Chan JWM, Ng CK, Tsang DNC, Lee MP, Li PCK. Clinical presentations and outcomes of *Penicillium marneffei* infections: a series from 1994 to 2004. *Hong Kong Med J* 2008; **14**: 103–9.
- 8 Hu Y, Zhang J, Li X *et al.* *Penicillium marneffei* infection: an emerging disease in mainland China. *Mycopathologia* 2013; **175**: 57–67.
- 9 Desakorn V, Simpson AJH, Wuthiekanun V, *et al.* Development and evaluation of rapid urinary antigen detection tests for diagnosis of penicilliosis marneffei. *J Clin Microbiol* 2002; **40**: 3179–83.
- 10 Wang YF, Cai JP, Di WY, *et al.* Immunoassays based on *Penicillium marneffei* Mp1p derived from *Pichia pastoris* expression system for diagnosis of penicilliosis. *PLoS ONE* 2011; **6**: 1–7.
- 11 Cao L, Chen DL, Lee C, *et al.* Detection of specific antibodies to an antigenic mannoprotein for diagnosis of *Penicillium marneffei* penicilliosis. *J Clin Microbiol* 1998; **36**: 3028–31.
- 12 Haynes KA, Westerneng TJ, Fell JW, Moens W. Rapid detection and identification of pathogenic fungi by polymerase chain reaction amplification of large subunit ribosomal DNA. *J Med Vet Mycol* 1995; **33**: 319–25.
- 13 Polanco A, Rodríguez-Tudela JL, Martínez-Suárez J. Detection of human pathogenic fungi in human blood by polymerase chain reaction. *Eur J Clin Microbiol Infect Dis* 1995; **14**: 618–21.
- 14 Sun J, Najafzadeh MJ, Zhang J, Vicente VA, Xi L, de Hoog GS. Molecular identification of *Penicillium marneffei* using rolling circle amplification. *Mycoses* 2011; **54**: e751–9.
- 15 Zeng H, Li X, Chen X, *et al.* Identification of *Penicillium marneffei* in paraffin-embedded tissue using nested PCR. *Mycopathologia* 2009; **168**: 31–5.
- 16 Pongpom M, Sirisanthana T, Vanittanakom N. Application of nested PCR to detect *Penicillium marneffei* in serum samples. *Med Mycol* 2009; **47**: 549–53.
- 17 Lu S, Li X, Calderone R, *et al.* Whole blood nested PCR and real-time PCR amplification of *Talaromyces marneffei* specific DNA for diagnosis. *Med Mycol* 2016; **54**: 162–8.
- 18 Pornprasert S, Praparattanapan J, Khamwan C, *et al.* Development of TaqMan real-time polymerase chain reaction for the detection and identification of *Penicillium marneffei*. *Mycoses* 2009; **52**: 487–92.
- 19 Cao L, Chan CM, Lee C, Wong SSS, Yuen KY. MP1 encodes an abundant and highly antigenic cell wall mannoprotein in the pathogenic fungus *Penicillium marneffei*. *Infect Immun* 1998; **66**: 966–73.
- 20 Wang Y, Xu H, Han ZZ-G, *et al.* Serological surveillance for *Penicillium marneffei* infection in HIV-infected patients during 2004–2011 in Guangzhou, China. *Clin Microbiol Infect* 2015; **21**: 484–9.